Sun Pharmaceutical Industries and Organon & Co. announced a definitive merger agreement on Sunday, April 26, 2026, in which Sun Pharma will acquire Organon for an enterprise value of $11.75 billion.
As part of the protective clauses in the merger agreement, a “Reverse Termination Fee” has been established. If the transaction is canceled under specific circumstances—primarily due to a failure to obtain necessary regulatory approvals or if Sun Pharma breaches the agreement—Organon will be entitled to a significant payout.
1. The $120 Million Termination Clause
While the full SEC filing (Schedule 14A) detailing every covenant is currently being finalized, preliminary deal summaries highlight the protection for Organon:
- The Penalty: If the deal is terminated by Sun Pharma due to regulatory roadblocks or a change in recommendation by Organon’s board (following a superior proposal), a termination fee of approximately $120 million (representing roughly 1% of the enterprise value) is payable.
- Purpose: This fee serves as a “break-up” protection, compensating Organon for the time, legal expenses, and potential stock volatility associated with a failed $11.75 billion acquisition.
2. Transaction Details
The deal represents the largest ever acquisition by an Indian pharmaceutical company.
| Metric | Detail |
| Offer Price | $14.00 per share (All-cash) |
| Enterprise Value | $11.75 Billion |
| Expected Closing | Early 2027 |
| Primary Goal | Move into Top 3 global Women’s Health & Top 10 Biosimilars. |
3. Strategic Rationale for Sun Pharma
By acquiring Organon (a 2021 spin-off from Merck & Co.), Sun Pharma is pivoting from a “Generic-first” firm to a global powerhouse in specialized medicine.
- Biosimilar Entry: Sun Pharma gains immediate access to Organon’s portfolio of biosimilars, including Brenzys and Hadlima.
- Women’s Health: Organon owns the global rights to Nexplanon (contraceptive implant) and a massive portfolio of established brands.
- Financial Synergy: The combined entity will have a revenue of approximately $12.4 billion, placing it among the top 25 pharmaceutical companies worldwide.
4. Regulatory Hurdles
The $120M cancellation fee is particularly relevant because the deal faces significant scrutiny in multiple jurisdictions:
- U.S. FTC Review: Given the size of the deal and the overlap in generic portfolios, the Federal Trade Commission is expected to demand divestitures in specific product categories.
- CCI Approval: The Competition Commission of India will review the deal for its impact on the domestic specialized medicine market.